Zacks Research Reduces Earnings Estimates for AngioDynamics

AngioDynamics, Inc. (NASDAQ:ANGO) – Investment analysts at Zacks Research cut their Q1 2027 EPS estimates for shares of AngioDynamics in a report issued on Tuesday, August 4th. Zacks Research analyst Team now anticipates that the medical instruments supplier will post earnings of ($0.09) per share for the quarter, down from their previous estimate of ($0.07). Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for AngioDynamics’ current full-year earnings is ($0.27) per share. Zacks Research also issued estimates for AngioDynamics’ Q2 2027 earnings at ($0.08) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.02) EPS, FY2027 earnings at ($0.24) EPS, Q1 2028 earnings at ($0.06) EPS, Q2 2028 earnings at ($0.07) EPS, Q4 2028 earnings at ($0.04) EPS and FY2028 earnings at ($0.17) EPS.

ANGO has been the subject of a number of other research reports. Canaccord Genuity Group upped their price target on AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a report on Friday, July 17th. Finally, HC Wainwright boosted their price objective on shares of AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, AngioDynamics has an average rating of “Hold” and a consensus price target of $19.50.

AngioDynamics Stock Performance

NASDAQ:ANGO opened at $15.04 on Thursday. The stock has a 50-day simple moving average of $13.01 and a 200 day simple moving average of $11.61. AngioDynamics has a 52-week low of $8.36 and a 52-week high of $15.41. The company has a market cap of $621.60 million, a PE ratio of -17.29 and a beta of 0.33.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.04. The firm had revenue of $86.61 million for the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS.

Insider Buying and Selling

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 23,370 shares of the business’s stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the transaction, the senior vice president owned 64,745 shares of the company’s stock, valued at approximately $953,046.40. The trade was a 26.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 6.00% of the company’s stock.

Hedge Funds Weigh In On AngioDynamics

A number of institutional investors have recently added to or reduced their stakes in the stock. Farther Finance Advisors LLC lifted its stake in AngioDynamics by 146.4% in the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 1,199 shares during the last quarter. Kemnay Advisory Services Inc. bought a new position in shares of AngioDynamics in the 4th quarter valued at $27,000. State of Wyoming acquired a new stake in shares of AngioDynamics during the 2nd quarter valued at $31,000. Russell Investments Group Ltd. increased its holdings in AngioDynamics by 329.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 3,213 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its position in AngioDynamics by 359.0% in the second quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock valued at $54,000 after purchasing an additional 4,268 shares during the last quarter. 89.43% of the stock is currently owned by institutional investors and hedge funds.

More AngioDynamics News

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: Zacks raised its fourth-quarter fiscal 2027 EPS forecast modestly to a loss of $0.02 from a loss of $0.03, indicating some improvement in that quarter’s outlook.
• Neutral Sentiment: Brokerages collectively maintain a consensus recommendation of “Hold” for AngioDynamics, providing a less bearish view than Zacks’ rating. AngioDynamics Given Consensus Recommendation of Hold by Brokerages
• Negative Sentiment: Zacks reduced its fiscal 2027 EPS forecast to a loss of $0.24 from a loss of $0.13. Estimates for the first three quarters were also cut, including Q3 2027 from a profit of $0.02 per share to a loss of $0.05.
• Negative Sentiment: Longer-term expectations weakened substantially: fiscal 2028 EPS was lowered to a loss of $0.17 from a loss of $0.04, while estimates for Q1 and Q2 fiscal 2028 were reduced to losses of $0.06 and $0.07, respectively.
• Negative Sentiment: Zacks also cut its Q3 2028 estimate from a profit of $0.03 to a loss of $0.01, while forecasting a fiscal 2029 loss of $0.15. The repeated downward revisions reinforce concerns about AngioDynamics’ path to profitability.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.